New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

1 Multiple myeloma originates in blood plasma cells — a type of cell found in bone marrow that is responsible for making antibodies. When these plasma cells become cancerous, they multiply ...

Study reveals VLCFA metabolism as a key target in multiple myeloma, enhancing drug efficacy and overcoming resistance.

Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...

A new advance may make it possible to use off-the-shelf CAR T cells provided by healthy donors. The new approach studied in mice equipped CAR T cells with the viral protein Nef.

Days after the European Commission (EC) granted approval, the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...

China NMPA approves Sanofi’s Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant: Paris Saturday, February 1, 2025, 12:00 Hrs [IST] The Nationa ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...